The Central Drugs Standard Control Organisation (CDSCO) has approved AstraZeneca Pharma India's application to import and distribute Enhertu (trastuzumab deruxtecan) for the treatment of HER2-positive breast cancer, marking a significant…
The Central Drugs Standard Control Organisation (CDSCO) has signalled a major shift in India’s drug regulatory framework, moving toward a risk-based approach designed to reduce compliance burdens for pharmaceutical manufacturers…
India's pharmaceutical sector must evolve beyond its traditional strength in generic medicines and build capabilities in complex generics, biologics, and research-driven drug development — that was the core message from…
The Central Drugs Standard Control Organization (CDSCO) has moved to curb a widespread but problematic practice in India's pharmaceutical market: using the same brand name across multiple, unrelated drug products…